Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma

Mikko Siurala1,2, Riikka Havunen1, Dipongkor Saha1, Dave Lumen3, Anu J. Airaksinen3, Siri Tähtinen1, Víctor Cervera-Carrascon1,2, Simona Bramante1, Suvi Parviainen1,2, Markus Vähä-Koskela1, Anna Kanerva1,4 and Akseli Hemminki1,2,5

INTRODUCTION

Adoptive T-cell transfer is a promising treatment approach for metastatic cancer, but efficacy in solid tumors has only been achieved with toxic pre- and post-conditioning regimens. Thus, adoptive T-cell therapies would benefit from complementary modalities that enable their full potential without excessive toxicity. We aimed to improve the efficacy and safety of adoptive T-cell transfer by using adenoviral vectors for direct delivery of immunomodulatory murine cytokines into B16.OVA melanoma tumors with concomitant T-cell receptor transgenic OT-I T-cell transfer. Armed adenoviruses expressed high local and low systemic levels of cytokine when injected into B16.OVA tumors, suggesting safety of virus-mediated cytokine delivery. Antitumor efficacy was significantly enhanced with adenoviruses coding for murine interleukin-2 (mIL-2) and tumor necrosis factor-α (mTNFα) when compared with T-cell transfer alone or viruses alone. Further improvement in efficacy was achieved with a triple combination of mIL-2, mTNFα, and OT-I T-cells. Mechanistic studies suggest that mIL-2 has an important role in activating T-cells at the tumor, while mTNFα induces chemokine expression. Furthermore, adenovirus treatments enhanced tumor infiltration of OT-I T-cells as demonstrated by SPECT/CT imaging of 111In-labeled cells. Our results suggest the utility of cytokine-coding adenoviruses for improving the efficacy of adoptive T-cell therapies.

Received 15 January 2016; accepted 20 June 2016; advance online publication 2 August 2016. doi:10.1038/mt.2016.137

This work was done in Helsinki, Finland.

Correspondence: Akseli Hemminki, Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Haartmaninkatu 3, 00290 Helsinki, Finland.
E-mail: akseli.hemminki@helsinki.fi

Molecular Therapy
RESULTS

Armed adenoviruses express biologically active murine cytokines in vitro

Transgenes were placed under the human cytomegalovirus promoter for constitutive expression of murine cytokines (Figure 1a). To confirm expression, supernatants from virus-infected cell cultures were analyzed for cytokines by enzyme-linked immunosorbent assay (ELISA) after a 48-hour incubation period (Figure 1b). Concentrations of in vitro-produced cytokines varied from 750 pg/ml (mIL-2) to 1,500 pg/ml (mTNFα). Functionality of the cytokines was confirmed with bioassays (Supplementary Figure S1). In conclusion, all viruses produced biologically active murine cytokines in vitro.

Intratumoral injection of virus results in high local and low systemic levels of cytokine

For the assessment of in vivo transgene expression, B16.OVA tumors were injected intratumorally with cytokine-armed adenoviruses (1 × 10⁹ VP/tumor). Tumor and serum were analyzed 72 hours later for cytokine content (Figure 1c–f). For all viruses, local expression of transgene was observed. From a safety perspective, it is noteworthy that very low levels of cytokines were detected in the serum.

Cytokine-armed adenoviruses combined with adoptive T-cell transfer inhibit the growth of B16.OVA tumors

Antitumor efficacy of adenovirus combined with OT-I cells was studied in C57BL/6 mice with established B16.OVA tumors (Figure 2). The animals received a single administration of 1.5 × 10⁶ CD8⁺ enriched OT-I T-cells and weekly injections of adenoviruses (1 × 10⁹ VP/injection). OT-I T-cell treatment only moderately suppressed tumor growth⁵ but when combined with Ad5-CMV-mIL2, significantly improved tumor growth control was observed when compared with both single agents and untreated control (combination versus Ad5-CMV-mIL2, P < 0.05; combination versus OT-I, P < 0.01; combination versus mock, P < 0.001) (Figure 2a). The combination of Ad5-CMV-mTNFα and OT-I T-cells inhibited tumor growth significantly over OT-I and mock alone (combination versus OT-I, P < 0.05; combination versus mock, P < 0.001), and a trend for improved efficacy was observed over virus alone (combination versus Ad5-CMV-mTNFα, P = 0.06) (Figure 2b). Ad5-CMV-mIFNγ combined with OT-I transfer resulted in tumor growth suppression that was significant compared with the virus alone and mock (combination versus Ad5-CMV-mIFNγ, P < 0.01; combination versus mock, P < 0.01), but not over OT-I alone (Figure 2c). For Ad5-CMV-IFNb, the addition of OT-I T-cells did not improve antitumor efficacy (combination versus Ad5-CMV-mIFNb, P = ns) but was superior to mock (combination versus mock, P < 0.001) (Figure 2d).

Double combination of Ad5-CMV-mTNFα and Ad5-CMV-mIL2 with T-cell transfer is superior to monotherapies against B16.OVA

From initial experiments performed with single cytokine-armed adenoviruses (Figure 2), two cytokines emerged as the most promising candidates for further studies (mTNFα and mIL-2). The viruses coding for these cytokines were subsequently combined in a 1 to 1 ratio together with OT-I T-cell transfer for the assessment of antitumor efficacy. Interestingly, the double combination of Ad5-CMV-mTNFα/Ad5-CMV-mIL2 (0.5 × 10⁹ VP each) with OT-I (1.5 × 10⁶ cells) was superior to the mTNFα-armed virus combined with OT-I (Ad5-CMV-mTNFα/Ad5-CMV-mIL2 + OT-I versus Ad5-CMV-mTNFα + OT-I, P < 0.05), the mIL2-armed virus combined with OT-I (Ad5-CMV-mTNFα/Ad5-CMV-mIL2 + OT-I versus Ad5-CMV-mIL2 + OT-I, P < 0.001) and OT-I treatment alone (Ad5-CMV-mTNFα/Ad5-CMV-mIL2 + OT-I versus OT-I, P < 0.001) (Figure 3).

Lymphocyte infiltrates in B16.OVA tumors following treatment with armed adenoviruses and OT-I transfer

Next, we examined endpoint B16.OVA tumors for clues on the mechanism of action behind the enhanced antitumor efficacy (Figure 4). First, the percentage of CD4⁺ and CD8⁺ T-cells in tumors were analyzed by flow cytometry. The highest percentage (11%) of CD4⁺ T-cells was observed in tumors treated with Ad5-CMV-mIL2 + OT-I (Figure 4a). The treatment groups that received Ad5-CMV-mIL2 only, Ad5-CMV-mTNFα/Ad5-CMV-mIL2 only and Ad5-CMV-mTNFα/Ad5-CMV-mIL2 + OT-I comprised 5–6% tumor-infiltrating CD4⁺ T-cells. The lowest CD4⁺ levels (1% of all cells) were observed in the OT-I only, Ad5-CMV-mTNFα only and Ad5-CMV-mTNFα + OT-I groups. The highest percentage of CD8⁺ T-cells (5% of all cells) were observed in the Ad5-CMV-mIL2 and Ad5-CMV-mTNFα/Ad5-CMV-mIL2 + OT-I groups (Figure 4b). The activation status of tumor-infiltrating T-cells after treatment was determined by CD69 staining of CD3-positive TIL (Figure 4c). Interestingly, the double cytokine combination (plus OT-I cells) resulted in a higher proportion of activated T-cells than seen in OT-I control group (Ad5-CMV-mTNFα/Ad5-CMV-mIL2 + OT-I versus OT-I, P < 0.05). Regulatory T-cells (Treg) were moderately increased in tumors treated with the triple combination of Ad5-CMV-mTNFα/Ad5-CMV-mIL2 + OT-I when compared with other treatment groups (Figure 4d). Besides T-cells, B-cell infiltration was increased in tumors treated with mIL2-coding viruses (Figure 4e). Increase in tumor-infiltrating natural killer cells (NK) was observed in the Ad5-CMV-mIL2 + OT-I and Ad5-CMV-mTNFα/Ad5-CMV-mIL2 + OT-I treatment groups (Figure 4f). Finally, low levels of immunosuppressive M2 macrophages were observed in tumors treated with combinations of cytokine-armed viruses and T-cells when compared with mTNFα and mIL2-coding viruses (Supplementary Figure S2a), and the number of mature dendritic cells (DC), as determined by cell-surface CD86 expression, was increased in the Ad5-CMV-mIL2 + OT-I-treated tumors (Supplementary Figure S2b).

PD1/PD-L1 pathway in B16.OVA tumors is affected by adenovirus treatment

In further mechanistic studies, we examined the immune check-point pathway involving Programmed cell death 1 (PD1) and its ligand PD-L1 in B16.OVA. OT-I transfer alone resulted in significant upregulation of PD-L1 expression as compared with untreated mock tumors and this effect was further enhanced by the addition of cytokine-coding adenovirus injections (Figure 5a).
Interestingly, Ad5-CMV-mIL2 + OT-I treatment resulted in a trend for PD1 downregulation on tumor-infiltrating CD8+ T-cells (Figure 5b).

**Virus-delivered mTNFα induces chemokine expression in tumors**

The expression of the chemokines RANTES, MCP1, MIP-1a, MIP-1b, MIG, and I-TAC was studied in homogenized B16.OVA tumor lysates (Figure 5c). When individual chemokine results were pooled, the combination treatment with Ad5-CMV-mTNFα + OT-I showed significant upregulation of these molecules when compared with OT-I alone (P < 0.0001) and Ad5-CMV-mIL2 + OT-I (P < 0.05).

**Adenovirus treatment increases tumor-infiltration of radiolabeled T-cells in SPECT/CT imaging**

The increased chemokine expression observed in virus-treated tumors prompted us to study the migration dynamics of adoptively transferred OT-I T-cells further. To this end, 111In-labeled OT-I T-cells were administered to B16.OVA tumor-bearing mice with simultaneous adenovirus injections (Figure 6). Intriguingly, SPECT/CT imaging of the mice revealed a significant accumulation of radiolabeled T-cells in the tumors of Ad5-CMV-mTNFα/Ad5-CMV-mIL2-treated mice compared with mock-treated mice (P = 0.03) 96 hours after treatment start (Figure 6a). The viruses coding for either cytokine alone were also able to induce OT-I cell migration to tumors, but the differences were not statistically significant. Representative SPECT/CT images of 96 hour imaging data are shown in Figure 6b.

**DISCUSSION**

Adoptive T-cell transfer is a promising treatment modality for advanced cancer. However, given its low efficacy in solid tumors, especially if toxic pre- and postconditioning is not used, complimentary approaches that enable the full potential of the approach are needed. To this end, we constructed murine cytokine-armed adenoviruses that were used together with OT-I T-cell transfer to treat B16 melanoma. Constitutive expression of murine cytokines from human serotype 5-based nonreplicating adenoviruses were confirmed in vitro and in vivo. TNFα was initially identified as one of the most potent molecules for destroying tumors.17 Subsequently, it has also been discovered that it can mediate important antitumor immunological effects.14,18 However, clinical trials with systemic recombinant TNFα have resulted in significant side effects, hepatotoxicity and hypotension being among the most common, while tumor responses have been rare.19 Thus, systemic delivery of TNFα results in significant off-target toxicities, which limit the concentration that can be achieved at the tumor, resulting in low efficacy. Therefore, recombinant TNFα is currently only used in isolated limb perfusion which physically restricts systemic exposure.20
Armed Adenoviruses Combined With T-cell Transfer

A more sophisticated approach for improving local to systemic TNFα levels is vectored delivery. This can be effectively achieved with armed adenoviruses as we show with Ad5-CMV-mTNFα; cytokine production was restricted to the intratumorally injected tumors while serum levels of mTNFα were negligible. Since the prototype adenoviral vectors (coding for murine transgenes) used in this study have no specificity for tumor cells, expression of cytokines from non-tumor cells is conceivable. However, in the case of replication-competent oncolytic adenoviruses, which express human transgenes, and which selectively replicate in tumor cells defective in the p16/Rb pathway,21 cytokine expression has been shown to be tumor-restricted with no systemic exposure.22

Delivery from an oncolytic platform is an optimal approach for achieving high acute levels of TNFα in the tumor. Not only is transgene expression linked to virus replication, which occurs only in tumors, but the transgene production platform, the virus genome, is amplified locally as long as viable tumor cells remain, and then shut off. Sustained long-term expression of TNFα is associated with carcinogenesis 23 while short term and dynamic expression can induce immune responses.18,24 Unfortunately, species-incompatibility issues prevent the use of replication-competent human adenoviruses in mice25 thus necessitating the development of nonreplicating and nonselective prototype vectors for preclinical studies such as performed in our paper.

Figure 2 Antitumor efficacy of cytokine-armed adenoviruses combined with adoptive T-cell transfer. B16-OVA tumor-bearing C57BL/6 mice were administered 1.5 × 10⁹ CD8-enriched OT-I T-cells intraperitoneally on Day 1 with concurrent intratumoral injections of 1 × 10⁹ viral particles of adenoviruses armed with (a) mIL2, (b) mTNFα, (c) mIFNg, and (d) mIFNb. Virus treatments continued every 7 days. Error bars, mean + SEM, n = 5–6. *P < 0.05, **P < 0.01, ***P < 0.001.

Figure 3 Ad5-CMV-mTNFα/Ad5-CMV-mIL2 dual virus combination together with adoptive T-cell transfer. Adenoviruses coding for mTNFα and mIL2 were combined in a 1 to 1 ratio (0.5 × 10⁹ VP of each virus) to treat B16-OVA tumors together with adoptive transfer of 1.5 × 10⁶ CD8-enriched OT-I T-cells. Virus treatments continued every 7 days. Error bars, mean + SEM, n = 8. *P < 0.05, ***P < 0.001.
IL-2 administration has been extensively studied as single agent therapy and in combination with adoptive TIL transfer in the treatment of melanoma. Systemically administered high-dose IL-2 together with preconditioning lymphodepletion and TIL infusion can lead to high response rates, but is accompanied by toxicity attributed to IL-2-induced vascular leakage syndrome. In contrast to toxicity, which occurs systemically at off-target organs, the useful effects if IL-2 on the T-cell graft occur locally at and near the tumor. Therefore, minimizing systemic exposure through local administration of IL-2 would seem preferable. As with Ad5-CMV-mTNFα, our data on intratumorally injected Ad5-CMV-mIL2 indicates that high local levels of cytokine can be achieved with minimal leakage to the circulation. With regard to clinical translation, the construction of replication-competent adenoviruses encoding human IL-2 (or other human cytokines) could yield a comparable safety profile due to...
were observed in the dual cytokine groups, indicating that the treatment was well-tolerated.32 More recently, clinical activity was observed in 17% of patients treated intralesionally with IL-2-coding adenoviruses (TG1024), and the treatments were safe.33 Significant tumor regressions have also been observed with TNFα-coding adenoviruses preclinically44,45 and in patients with advanced solid tumors.35 Of note, recombinant TNFα and IL-2 seem attractive for enhancing adoptive cell therapy.46 Together with these previous reports, our data supports the notion that IL-2 and TNFα-coding adenoviruses have translational potential in the context of enabling safe and effective T-cell therapy of humans with currently incurable solid tumors.

To further improve antitumor efficacy, we combined the two most promising cytokines from initial experiments, i.e., mIL-2 and mTNFα, with concurrent OT-I T-cell transfer. With Ad5-CMV-mIL2 and Ad5-CMV-mTNFα mixed together, the growth of B16.OVA tumors was significantly reduced when compared with single agent therapies. Moreover, no treatment related deaths were observed in the dual cytokine groups, indicating that the treatment was well-tolerated. Our data is in line with earlier studies which revealed a synergistic relationship between recombinant IL-2 and TNFα against various murine tumors.37,38 With regard to mechanism of action, our data suggests that TNFα has a role in recruiting T-cells (through induction of chemokine expression) that is further enhanced by the addition of IL-2 as shown in the SPECT/CT imaging experiment. Previous research supports our observations, as tumor-targeted TNFα has been shown to enhance lymphocyte infiltration and adoptive T-cell therapy.39,40 TNFα may also be important in counteracting immunosuppression, including M2 macrophages, when used in combination with IL-2 and T-cell therapy. It could also be of relevance that TNFα has been suggested to suppress regulatory T-cell function.41 In humans, however, no antitumor effects have been seen with systemically administered cytokines nor has the combination treatment been well-tolerated.42 The discrepancy between human and mouse data underscores the difficulty of translating rodent results directly into humans, one cause of which is the higher ability of the former to sustain doses which would be lethal in the latter. Moreover, these data emphasize the utility of local cytokine production, because it allows effective local concentrations to be obtained with limited systemic exposure. Clearly, only human data can ultimately determine the feasibility of combining IL-2/TNFα-coding adenoviruses with adoptive T-cell transfer.

The dual role of IL-2 as a promoter and inhibitor of antitumor immune responses is well-established.43 Concordantly, our previous research with recombinant murine IL-2 and OT-I in the B16.OVA model has revealed that simultaneous antitumor (i.e., dendritic cell activation) and immunosuppressive (i.e., Tregs) pathways appear to be induced with IL-2 (ref. 36). In line with
these observations are reports where IL-2-transduced B16 tumors exhibited improved tumor growth control and increased NK cells and effector T-cells despite increases in infiltrating regulatory T-cells. In the experiments described here, B16.OVA tumors treated with Ad5-CMV-mlIFNγ, Ad5-CMV-mlIFNβ and Ad5-CMV-mTNFα were constructed by inserting expression cassettes with murine cytokines. 

Cytokine functionality. 293 cells were infected with 100 viral particles/cell (VP/cell) with cytokine-coding viruses and Ad5lac1 (negative control) (8 replicate wells per virus). Supernatants were collected 48 hours later and filtered through 0.02 μm inorganic membrane filters. The bioactivity of mIL-2 present in the supernatant was confirmed with B16-Blue IFN-α/β murine type I IFNs sensor cells following manufacturer’s instructions. TNFα-sensitive mouse L-292 cells were used to confirm the functionality of mTNFα by coculturing the supernatant with L-292 cells seeded on a 96-well plate (1 × 10⁴ cells/well) for 24 hours before determining cell viability using the MTS assay. 

Transgene expression. Cytokine production in vitro was measured from cell culture supernatants of virus-infected 293 cells (three replicate wells per virus) with ELISA kits: mIFNg (Abcam, Cambridge, UK), mIFNβ (PBL InterferonSource, Piscataway, NJ), mIL-2 and mTNFα (IBL International, Hamburg, Germany). In vivo expression of cytokines was studied in C57BL/6 mice (Harlan Laboratories, Indianapolis, IN) implanted subcutaneously with B16.OVA tumors and injected once with 1 × 10⁴ VP intratumorally (n = 2–4). 72 hours later, the tumors were snap-frozen on dry ice and stored at −80 °C. Cytokine measurements were performed with CBA Flex Sets (BD, Franklin Lakes, NJ) as previously described and normalized to total protein content.

Virus treatments. 0.25 × 10⁶ B16.OVA cells were injected subcutaneously into C57BL/6 mice (Harlan Laboratories) and tumors were allowed to develop until reaching a size feasible for injection. The mice were injected intratumorally with 1 × 10⁴ VP/tumor (or 0.5 × 10⁴ VP of each virus in TNFa/IL2 combination treatments) in 50 μl of PBS on the same day as CD8+ enriched OT-1 T-cells were administered (described below). Virus treatments continued every 7 days and tumors were measured with digital calipers every 2–3 days. n = 5–6 animals per group.

Adaptive T-cell transfer. Splenocytes from OT-1 TCR transgenic mice (The Jackson Laboratory, Bar Harbor, ME) were cultured in the presence of 160 ng/ml mIL-2 (R&D Systems) and 300 ng/ml anti-mouse CD3e (clone 145-2C11, eBioscience, San Diego, CA) for 3 days before enrichment of CD8+ cells was performed with CD8a+ T cell Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany) according to manufacturer’s
Armed Adenoviruses Combined With T-cell Transfer

instructions. Enriched T-cells were cultured further in the presence of mIL-2 and anti-CD3ε for 7 days before adoptive transfer into B16.OVA tumor-bearing mice. The mice received 1.5 x 10^10 CD8+ enriched OT-1 T-cells intraperitoneally in 100 µl of plain RPMI. All animal protocols were reviewed and approved by the Experimental Animal Committee of the University of Helsinki and the Provincial Government of Southern Finland.

Flow cytometry. Flow cytometric analyses were performed according to procedures established earlier in our group. Briefly, excised tumors were pushed through 70 µm cell strainers and cultured overnight in complete RPMI 1640 medium before storing the single-cell suspension at −80 °C for later analysis.

Chemokine expression. Established B16.OVA tumors were treated once with adenoviruses and OT-1 cells. 7 days later the tumors were collected, snap-frozen and stored in −80 °C. Tumor homogenization and chemokine analysis was performed with BD CBA Flex Sets as previously described. OT-I radiolabeling and SPECT/CT imaging was performed as previously described. Briefly, excised tumors were imaged with a preclinical four-headed gamma camera with integrated CT system (nanoSPECT/CT, Bioscan). The results were calculated as percentage of activity in tumor from the injected dose divided by the activity in normal liver. The authors wish to thank Susanna Grönberg-Vähä-Koskela, Sanna Merisalo-Soikkeli, Milla Siruara, Mari Arokainen, Aj et al. (2015). Adenovirus improves the efficacy of adoptive T-cell therapy by recruiting immune cells to and promoting their activity at the tumor.

Statistical analyses. Statistics were performed with GraphPad Prism 6. Values of <0.05 were considered significant.

SUPPLEMENTARY MATERIAL Figure S1. Cytokine functionality. Figure S2. In-oxine radiolabeling and SPECT/CT imaging. In-oxine radiolabeling and SPECT/CT imaging was performed as previously described. Briefly, 6 x 10^10 CD8+ enriched OT-1 T-cells were labeled with In-oxine for 15 minutes and injected intraperitoneally into recipient mice (5.9 ± 0.3 MBq per animal). On days 1, 2, and 4 after administration of radiolabeled cells, virus-treated (n = 5 per virus group) and mock-treated (n = 3 mice) were imaged with a preclinical four-headed gamma camera with integrated CT system (nanoSPECT/CT, Bioscan). The results were calculated as percentage of activity in tumor from the injected dose divided by the tumor volume (mm^3).

ACKNOWLEDGMENTS A.H. is shareholder in Targovax ASA. A.H. is employee and shareholder in TILT Biotherapeutics Ltd. M.S. and S.P. are employees of TILT Biotherapeutics Ltd. Other coauthors declare no potential conflict of interest. The authors wish to thank Susanna Grönberg-Vähä-Koskela, Marjo Vaha and Minna Oksanen for expert assistance.


